Semaglutide and diabetes recovery stories

A June 2026 paper in Medical Humanities by Kieran Fionn Murphy (University College Cork) examines a question that sits just outside the clinical trial literature: what story do patients tell themselves when they recover from type 2 diabetes, and what does semaglutide do to that story?^[1] The answer, Murphy argues, is more complicated than either "willpower won" or "the drug fixed it."

What is a redemptive narrative

Redemptive narratives are storytelling frameworks built on three moves: a period of deficiency or failure, a turning-point event, and a renewal that lets the protagonist influence others. Murphy traces the structure back to Augustine's Confessions and identifies the same pattern in two well-known metabolic illness memoirs: William Banting's 1863 Letter on Corpulence, where the author credits a low-carbohydrate regimen with rescuing him from obesity, and Tom Watson's 2020 Downsizing, where the former UK Labour Party leader narrates reversing his type 2 diabetes through dietary change. Both authors cast themselves as changed subjects with a duty to spread the method. Both claim agency at the centre of their recovery.

The redemptive structure is appealing, Murphy notes, because it gives the person with diabetes a role beyond passive recipient of treatment. It is also, the paper argues, where the tension begins.

The free will problem in metabolic illness

Obesity and type 2 diabetes sit at the intersection of biology and behaviour, which makes them unusually vulnerable to moral framing. Research on weight stigma has documented the cost: people with obesity are more likely to delay seeking care, less likely to receive adequate treatment, and more likely to internalise the view that their condition reflects a character flaw^[2]. The redemptive narrative, however well-intentioned by the person telling it, can sharpen this problem. If recovery is framed as proof that the author had the will to change, the logical implication is that those who have not recovered lacked that will.

Murphy's paper identifies this as a structural feature of the genre, not a flaw unique to any individual memoirist. Both Banting and Watson wrote before the GLP-1 class existed. Their agency claims were built on dietary and lifestyle change. What happens to the redemptive narrative when a weekly injection does a significant share of the biological work?

Where semaglutide complicates the story

The arrival of semaglutide and the broader GLP-1 class creates a new narrative pressure. Patients who experience remission on Ozempic face a cultural question the drug itself cannot answer: am I the agent of this recovery, or is the molecule? Critics of the medication in popular discourse have framed it as the "easy way out," while users have sometimes described feeling stigmatised for relying on pharmacotherapy rather than lifestyle change alone. This mirrors criticism historically directed at bariatric surgery.

Murphy does not argue that patients are wrong to feel a sense of agency over their recovery. The paper's position is more precise: the redemptive narrative frame, borrowed from a long literary tradition, pushes the story toward personal agency and away from the biological and social determinants that shaped the illness in the first place. This is partly an artefact of how memoir works as a genre. Autobiographical accounts by definition foreground the self. The same pressure shows up in social media discussions of Ozempic and tirzepatide, where users narrate before-and-after journeys that follow the same three-move structure.

Why the framing matters beyond the memoir shelf

Medical humanities research of this kind is not primarily addressed to patients. It is addressed to clinicians, policymakers, and health communicators who shape the environment in which patients understand their conditions. Murphy's argument, as reported in the paper, is that the redemptive narrative structure contributes to stigma by reinforcing a model of metabolic illness that centres individual will. In the GLP-1 era, when remission is more pharmacologically accessible than at any prior point, clinicians and communicators have a chance to offer a different frame: one that acknowledges the biological complexity of obesity and type 2 diabetes alongside the real role patients play in managing their health. The June 2026 ACP guideline that placed semaglutide and tirzepatide first-line for obesity was notable for grounding its recommendation in pharmacological evidence rather than framing the drugs as substitutes for patient effort.

A 2025 review in Current Obesity Reports by Berit Heitmann^[2] reached a compatible finding from a different angle. Heitmann noted that GLP-1 agonists may help shift public perceptions of obesity away from moral failure toward medical condition, but that paradoxically some users face stigma for taking what critics characterise as a pharmacological shortcut. Heitmann also flagged that high drug costs create access disparities that can intensify existing biases against those who cannot afford treatment.

What this does not settle

Murphy's paper is a humanities argument, not a clinical intervention. It does not report patient-level outcomes, trial data, or remission rates. The paper is an analysis of narrative structure in a small set of texts. It does not tell any individual patient how to understand their own recovery, and it does not prescribe a particular communication framework for clinicians. What it offers is a precise account of why the language around diabetes remission carries moral weight that the pharmacology alone does not explain, and why that weight matters when semaglutide is making remission a realistic prospect for a larger population than ever before.

Readers interested in the clinical evidence behind semaglutide's effects on type 2 diabetes and weight management can find a summary of the trial programme on the semaglutide peptide page. For the comparable evidence on tirzepatide, see that peptide page. This article covers the cultural and humanities dimension of these drugs, which is a separate question from dosing, safety, or regulatory status. Nothing in this article constitutes medical advice. Any decision about managing type 2 diabetes or obesity, including decisions about pharmacotherapy, belongs with a qualified healthcare provider.